Ionis Pharmaceuticals (IONS) Dropped, So What Is Behind The Latest Attention?

Why the TRYNGOLZA decision matters for Ionis Pharmaceuticals

Ionis Pharmaceuticals (IONS) is back in focus after European regulators issued a positive opinion on extending TRYNGOLZA’s indication for adults with severe hypertriglyceridemia, adding a fresh catalyst to the stock’s story.

Recent trading has been rough for Ionis Pharmaceuticals, with the share price down 22.37% over the past 90 days and the year to date share price return declining 46.12%, even though the 5 year total shareholder return is still up 30.09%. The TRYNGOLZA update arrives against that backdrop. The mixed return profile suggests investors are reassessing both the perceived risk in the pipeline and the long term potential for the broader RNA medicines portfolio at the current US$42.93 share price.

Scan beyond Ionis Pharmaceuticals and see how other RNA and biotech players are priced today by running the hand picked 29 high quality undervalued stocks alongside this TRYNGOLZA catalyst story.

After a drop of more than 40% over the past year, Ionis Pharmaceuticals now sits at US$42.93 with a fresh TRYNGOLZA catalyst in hand. Is most of the rerating already gone, or is meaningful upside still on the table?

Most Popular Narrative: 49% Undervalued

Against the last close at $42.93, the most followed valuation narrative for Ionis Pharmaceuticals points to a fair value of $83.64, and frames TRYNGOLZA and the severe hypertriglyceridemia opportunity as central to the story.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage. Expanding addressable patient populations, from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.

See why 20 investors see Ionis Pharmaceuticals as 49% undervalued.

Result: Fair Value of $83.64 (UNDERVALUED)

Still, the Ionis Pharmaceuticals story depends heavily on a smooth TRYNGOLZA rollout in severe hypertriglyceridemia and on regulators signing off on key late stage programs.

Find out about the key risks to this Ionis Pharmaceuticals narrative.

Next Steps

If this TRYNGOLZA driven optimism for Ionis Pharmaceuticals feels compelling, act quickly by pulling up the data and stress testing it against your own expectations. Then round out your view by checking the 3 key rewards

Looking for more investment ideas beyond Ionis Pharmaceuticals?

Do not stop your research with Ionis Pharmaceuticals. Broaden your watchlist now so you are not late to the next opportunity with strong fundamentals and clear catalysts.

• Target stability and income by reviewing a curated group of resilient payers through the 5 dividend fortresses.
• Hunt for mispriced quality by running the 21 high quality undiscovered gems and spotting companies the market may be overlooking.
• Prioritise defense first by scanning financially robust businesses using the list of solid balance sheet and fundamentals (24 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com